Patients on immunosuppressive therapy have an increased risk of infections. Since infections have a potential to trigger acute porphyric attacks vigilance is motivated regarding signs or symptoms of infection and/or possible symptoms of a porphyric attack. Side effects like nausea and vomiting may potentially be porphyrinogenic through reduction in carbohydrate intake.

Infections are common in patients using immunosuppressants and since infections might trigger an acute porphyric attack, vigilance regarding signs and symptoms of an infection and/ or a porphyric attack is recommended. Common adverse reactions of basiliximab that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.

Antibody preparation with no CYP metabolism. Based on the pharmacokinetics, basiliximab is not expected to have any porphyrinogenic effects.

Basiliximab is a chimeric human-murine monoclonal antibody against IL2, which inhibits IL2 - mediated lymphocyte activation.

Basiliximab is used as prophylaxis of acute organ rejection in renal transplantation together with ciclosporin and steroids. It is administered as an intravenous injection or infusion.

The metabolism of basiliximab is expected to be similar as for endogenous antibodies, which are metabolised to peptides and amino acids in various body tissues and in plasma by circulating phagocytic cells or by their target antigen-containing cells.